SDI Group plc
("SDI", "SDI Group", the "Company", or the "Group")
Interim results for the six months ended 31 October 2020
SDI Group plc, the AIM quoted Group focused on the design and manufacture of scientific and technology products for use in digital imaging and sensing and control applications, is pleased to announce another strong set of results and solid operational progress for the six months to end October 2020.
Financial Highlights
· Revenue increased 23% to £14.13m (2019: £11.45m) including 7.7% organic growth
o Strong contribution from products designed into equipment used in testing for and treating COVID-19, offset by impact of the pandemic on the broader economy
· Adjusted operating profit* for the period increased 52% to £3.20m (2019: £2.10m)
o Reported operating profit increased 56% to £2.53m (2019: £1.62m)
· Adjusted profit before tax* increased 52% to £3.03m (2019: £2.00m)
o Reported profit before tax increased 56% to £2.37m (2019: £1.52m)
· Adjusted diluted EPS* increased 45% to 2.47p (2019: 1.70p)
o Reported diluted EPS increased 48% to 1.95p (2019: 1.32p)
· Cash generated from operations increased 130% to £4.72m (2019: £2.05m)
· Net debt** at 31 October 2020 is £0.34m (30 April 2020: net debt of £4.04m)
* before reorganisation costs, acquisition costs, amortisation of acquired intangibles and share based payment costs
** bank finance less cash and cash equivalents
Operational Highlights
· While maintaining safe working conditions, the Group has adapted to changing patterns of demand and has dramatically increased capacity and output in areas where its products could contribute to the global response to the COVID-19 pandemic
· Post period end, acquisition of Monmouth Scientific Limited
Ken Ford, Chairman of SDI Group, said:
"We are pleased to report another strong set of financial results. I would like to thank all our staff for their hard work and ability to rapidly adapt to changing working environments. Our business model has shown resilience in the period and despite the ongoing uncertainties, the Board remains confident that SDI will deliver a full year financial performance in line with market expectations."
Enquiries
SDI Group plc 01223 320480
Ken Ford, Chairman
Mike Creedon, CEO
Jon Abell, CFO
finnCap Ltd 020 7220 0500
Ed Frisby/Kate Bannatyne - Corporate Finance
Andrew Burdis/Sunila de Silva - ECM
JW Communications 07818 430877
Julia Wilson - Investor & Public Relations
About SDI Group plc:
SDI designs and manufactures scientific and technology products for use in digital imaging and sensing and control applications including life sciences, healthcare, astronomy, manufacturing, precision optics and art conservation. SDI operates through its company divisions: Atik Cameras, Synoptics, Graticules Optics, Sentek, Astles Control Systems, Applied Thermal Control, MPB Industries, Chell Instruments and Monmouth Scientific.
SDI continues to grow by developing its own technology advancements and by improving its global sales channels, as well as through pursuing strategic, complementary acquisitions. www.thesdigroup.net
Chairman's statement
Despite the coronavirus pandemic, for the six month period ended October 2020, the SDI Group plc is pleased to report revenues, adjusted profit before tax and profits before tax, all significantly higher than the equivalent six month period ended 31 October 2019. Although trading conditions remain challenging, the need for digital imaging and sensing and control products in the life science and medical industries has been robust and during this pandemic, some of our companies have been awarded large one-off contracts to supply equipment to help test for, or treat, COVID-19. These contracts have ensured that the Group is trading broadly in line with forecasts set prior to the pandemic.
During the period the Group put in place measures for a safe working environment for our staff to continue to manufacture products which are essential in the fight against the COVID-19 pandemic. Changes to our working practices and reorganising our work force to keep our staff safe allowed us to keep all operation open throughout the period.
Trading
Across the Group, orders were negatively impacted at the beginning of the half year, in May 2020, but began to steadily increase as the global lockdown eased and demand returned. By September 2020 order intake had returned to near pre-pandemic expectations with many of our businesses fulfilling order to supply OEM products for contracts which had previously been put on hold by our major industrial and life science equipment customers.
Revenues
Group revenues for the period ended October 2020 increased by 23% to £14.13m (2019: £11.45m) including 7.7% organic growth.
Sales in our digital imaging reporting segment grew by 23% to £6.94m (2019: £5.64m). The increase in turnover has come from a one-off contract related to the supply of equipment to test for COVID-19 awarded to Atik and from sales of systems being manufactured at the Synoptics site. Synoptics has posted good revenues with its Synbiosis division having a record month for turnover in October 2020.
The sensing and control reporting segment showed overall positive turnover growth of 24%, due to the contribution from MPB of a one-off contract completed during the period to supply 40,000 flowmeters for production of Rapidly Manufactured Ventilator Systems to treat COVID-19 patients, and to the revenues generated by Chell Instruments acquired after the October 2019 period end.
Profits
Group profit before tax increased by 56% to £2.37m (2019: £1.52m). The increase in profitability was driven by organic revenue growth, Chell Instruments (acquired after the period ended October 2019) and reduced overheads. During the reporting period, the Group has been actively reducing its overall costs, with the largest decrease in overheads coming from reduction in salary costs. At our UK and US-based facilities within the Group where orders were negatively impacted by the COVID-19 pandemic we furloughed 19% of our workforce during the period under UK and US Government job retention schemes. Staff are returning to working at pre-pandemic levels to fulfil orders which were largely deferred due to the global lockdown. We continue to monitor our forecasts against the background of second wave lockdowns and potential Brexit disruption and any supply-chain issues these could cause.
In addition to GAAP results, the Group also provides adjusted results in which certain one-time and non-cash charges are excluded, to help shareholders understand the underlying operating performance. Adjusted operating profit increased by 52% to £3.20m (2019: £2.10m).
Basic earnings per share increased by 48% from 1.37p to 2.03p; diluted earnings per share also increased by 48% to 1.95p (2019: 1.32p). Adjusted diluted EPS increased by 45% to 2.47p (2019: 1.70p).
Cash flow
Cash generated from operations increased by 130% to £4.72m (2019: £2.05m). Contributing to this was a reduction in average debtor days in both reporting segments and the Group benefitting from a substantial increase in advanced payments at Atik Cameras. These have contributed to a substantial reduction in net debt in the period. Net bank debt, or bank debt less cash, reduced to £0.34m at 31 October 2020 from £4.04m at 30 April 2020.
Operations and COVID-19
Following UK government guidelines around social distancing and hygiene, SDI has invested during the period to make our manufacturing facilities COVID-19 safe. We operate manufacturing in many sites across the UK and in addition have a manufacturing site in Portugal. We have been able to put protocols in place to keep each facility operational while minimizing risk to our employees. Production staff are now back working full-time in our manufacturing facilities, indeed, many did not stop during lockdown and our sales and administration teams currently operate a shift system, with time working from home and in the office. To date, these measures, alongside our staff's diligence and hard work, has meant we have been minimally impacted by COVID-19 infections among our employees.
Our planned expansion of the Atik production site in Lisbon, Portugal was successfully completed in the first quarter of 2020. Having the site operational with twice the manufacturing capacity has allowed Atik to safely work on a significant one-off contract to manufacture cameras for RT-PCR testing equipment (DNA amplification) to detect the virus which causes COVID-19. Atik expects to complete delivery of the order by February 2021. This date ties in with the timing of Atik's OEM contract with a major life science equipment supplier resuming to similar levels as previously experienced..
Acquisitions
On 2 December 2020, after the interim period end, SDI acquired Monmouth Scientific Limited ("Monmouth Scientific") for an initial consideration of £2.66m in cash and shares in SDI Group plc. Further payments will be made up to a maximum total consideration of £6.94 million depending on net assets delivered at completion and on profits made by Monmouth Scientific in the 12 months to 31 March 2021, and these will be funded through our existing cash and loan facilities. Monmouth Scientific specialises in the design, manufacture and service of clean air solutions for a variety of scientific, medical and other technical sectors, protecting the purity of the air of both the controlled activity and of the operator. Principal products are bespoke and modular cleanrooms, biological safety cabinets, fume cupboards and laminar flow cabinets. For the year ended 31 March 2020 the Company achieved revenues of £6.2m, and profit before tax of £0.28m. The Acquisition is in line with the Group's strategy of acquiring complementary businesses serving scientific, medical and other technical sectors with capable management teams in place and with opportunities to grow further under the SDI Group structure. Monmouth Scientific will be part of SDI Group's Sensors and Control reporting segment. The acquisition is in line with our previously announced strategy of organic and acquisitive growth and is expected to be immediately earnings enhancing.
The Group continues to look for complementary acquisitions fitting our criteria, and we would hope to identify at least one that we can complete in 2021.
Outlook
The SDI Group's diversified portfolio of companies has meant that we have been protected against the worst of the commercial downturn caused by the pandemic and some companies in our Group have secured significant one-off contracts because of it. The Board would like to thank all our staff for their hard work and ability to rapidly adapt to changing working environments which have all contributed to help secure SDI's stability and future growth. Due to the resilience of our business model to date, and despite the potential for economic variability, influenced by possible second or third wave global lockdowns, political conditions (including Brexit) and currency fluctuations, the Board is confident that SDI will deliver a full year financial performance in line with market expectations.
Ken Ford, Chairman
8th December 2020
Product Portfolio
Digital Imaging
The digital imaging segment consists of three divisions, Atik Cameras, Graticules Optics and Synoptics.
Atik Cameras
Atik Cameras offers three brands of camera:
(a) Atik - highly sensitive cameras for life science and industrial applications, as well as deep-sky astronomy;
(b) Quantum Scientific Imaging (QSI) - high performance cameras with applications in astronomy, life science and flat panel display inspection; and
(c) Opus Instruments - infrared reflectography cameras for art conservation and restoration.
Graticules Optics
Designs and manufactures precision micro pattern products on glass, film and metal foil.
Synoptics
Offers a range of instruments under four brands:
(a) Syngene - advanced systems for documentation and analysis of gels for molecular biologists. This brand utilises some of the range from Atik Cameras;
(b) Synbiosis - equipment for microbiologists to automate colony counting and zone measurement;
(c) Synoptics Health - ProReveal, to detect residual proteins on surgical instruments; and
(d) Fistreem - water purification products and vacuum ovens.
Sensors and Control
The sensors and control segment currently encompass six divisions: Applied Thermal Control and Thermal Exchange, Astles Control Systems, Chell Instruments, MPB Industries, Sentek and Monmouth Scientific,
Applied Thermal Control and Thermal Exchange
Applied Thermal Control and Thermal Exchange have been merged into a single division and manufacture and supply chillers, coolers and heat exchangers used within industrial, medical and scientific markets.
Astles Control Systems
Astles is a supplier of chemical dosing and control systems to manufacturing customers worldwide.
Chell Instruments
Specialises in the design, manufacture and calibration of pressure, vacuum, and gas flow measurement instruments for a variety of sectors including aerospace, vehicle aerodynamics, gas and steam turbine testing and power generation industries.
MPB Industries
Designs and manufactures flowmeters and other equipment for measuring liquids and gases for industrial and scientific applications.
Sentek
Sentek manufactures and markets off-the-shelf and custom-made, reusable and single-use electrochemical sensors for use in laboratory analysis, food, beverage, pharmaceutical and personal care manufacturing, as well as the leisure industry.
Monmouth Scientific
Acquired on 2 December 2020. The company designs, manufactures and services clean air solutions specialising in cleanrooms, biological safety fume cupboards and laminar flow cabinets
Consolidated income statement
Unaudited for the six months ended 31 October 2020
Note |
| 6 months to 31 October 2020 Unaudited £'000 |
| 6 months to 31 October 2019 Unaudited £'000 |
| 12 months to 30 April 2020 Audited £'000 | |
Revenue |
|
| 14,126 |
| 11,445 |
| 24,498 |
Costs of sales |
|
| (4,724) |
| (3,680) |
| (7,899) |
Gross Profit |
|
| 9,402 |
| 7,765 |
| 16,599 |
|
|
|
|
|
|
|
|
Other operating income |
|
| 7 |
| - |
| 19 |
Operating expenses |
|
| (6,874) |
| (6,144) |
| (13,107) |
|
|
|
|
|
|
|
|
Analysed as: |
|
|
|
|
|
|
|
Reorganisation costs |
| (129) |
| (59) |
| (110) |
|
Share based payments |
| (152) |
| (140) |
| (276) |
|
Acquisition and fundraising costs |
| - |
| - |
| (58) |
|
Amortisation of acquired intangible assets |
|
(379) |
|
(282) |
|
(647) |
|
Expected credit loss |
| - |
| - |
| (165) |
|
Other operating costs |
| (6,214) |
| (5,663) |
| (11,851) |
|
Operating expenses |
| (6,874) |
| (6,144) |
| (13,107) |
|
|
|
|
|
|
|
|
|
Operating profit |
|
| 2,535 |
| 1,621 |
| 3,511 |
Net financing expense |
|
| (164) |
| (104) |
| (254) |
Profit before taxation |
|
| 2,371 |
| 1,517 |
| 3,257 |
Income tax charge |
|
| (393) |
| (189) |
| (666) |
Profit for the period |
|
| 1,978 |
| 1,328 |
| 2,591 |
Earnings per share | 5 |
|
|
|
|
|
|
Basic earnings per share |
|
| 2.03p |
| 1.37p |
| 2.66p |
Diluted earnings per share |
|
| 1.95p |
| 1.32p |
| 2.56p |
Consolidated statement of comprehensive income
Unaudited for the six months ended 31 October 2020
|
| 6 months to 31 October 2020 Unaudited £'000 | 6 months to 31 October 2019 Unaudited £'000 | 12 months to 30 April 2020 Audited £'000 |
Profit for the period |
| 1,978 | 1,328 | 2,591 |
Other comprehensive income |
|
|
|
|
Exchange differences on translating foreign operations |
|
48 |
26 |
41 |
Total comprehensive profit for the period |
|
2,026 |
1,354 |
2,632 |
Consolidated balance sheet
Unaudited at 31 October 2020
| Note | 31 October 2020 Unaudited £'000 | 31 October 2019 Unaudited £'000 | 30 April 2020 Audited £'000 |
Assets |
|
|
|
|
Non-current assets |
|
|
|
|
Intangible assets |
| 21,110 | 16,900 | 21,650 |
Property, plant and equipment |
| 3,584 | 3,281 | 3,901 |
Deferred tax asset |
| 219 | 182 | 246 |
|
| 24,913 | 20,363 | 25,797 |
Current assets |
|
|
|
|
Inventories |
| 4,087 | 2,785 | 3,728 |
Trade and other receivables |
| 4,456 | 3,425 | 3,617 |
Cash and cash equivalents |
| 3,436 | 2,727 | 5,290 |
|
| 11,979 | 8,937 | 12,635 |
Total assets |
| 36,892 | 29,300 | 38,432 |
Liabilities |
|
|
|
|
Non-current liabilities |
|
|
|
|
Borrowings | 6 | 2,400 | 3,300 | 7,962 |
Lease liabilities | 6 | 2,211 | 2,058 | 2,414 |
Deferred tax liability |
| 2,037 | 1,356 | 2,134 |
|
| 6,648 | 6,714 | 12,510 |
Current liabilities |
|
|
|
|
Trade and other payables |
| 5,412 | 2,927 | 3,350 |
Provisions for warranty |
| 85 | 16 | 85 |
Borrowings | 6 | 1,371 | - | 1,371 |
Lease liabilities | 6 | 562 | 449 | 539 |
Current tax payable |
| 510 | 597 | 513 |
|
| 7,940 | 3,989 | 5,858 |
Total liabilities |
| 14,588 | 10,703 | 18,368 |
Net assets |
| 22,304 | 18,597 | 20,064 |
Equity |
|
|
|
|
Share capital |
| 978 | 972 | 975 |
Merger reserve |
| 3,030 | 3,030 | 3,030 |
Share premium account |
| 8,805 | 8,696 | 8,746 |
Share-based payment reserve |
| 619 | 424 | 467 |
Foreign exchange reserve |
| 229 | 166 | 181 |
Retained earnings |
| 8,643 | 5,309 | 6,665 |
Total equity |
| 22,304 | 18,597 | 20,064 |
Consolidated statement of cash flows
Unaudited for the six months ended 31 October 2020
| 6 months to 31 October 2020 Unaudited £'000 | 6 months to 31 October 2019 Unaudited £'000 | 12 months to 30 April 2020 Audited £'000 |
Operating activities |
|
|
|
Profit for the period | 1,978 | 1,328 | 2,591 |
Depreciation, amortisation and impairment | 1,096 | 919 | 2,020 |
Finance costs and income | 164 | 104 | 254 |
Impairment of intangibles | 18 | - | 22 |
Changes in provisions | - | 5 | 74 |
Taxation expense in the income statement | 393 | 189 | 666 |
Employee share-based payments | 152 | 140 | 276 |
Operating cash flow before movement in working capital | 3,801 | 2,685 | 5,903 |
|
|
|
|
Changes in inventories | (400) | (201) | (539) |
Changes in trade and other receivables | (745) | (94) | 726 |
Changes in trade and other payables | 2,059 | (339) | (921) |
Cash generated from operations | 4,715 | 2,051 | 5,169 |
|
|
|
|
Interest paid | (164) | (104) | (253) |
Income taxes paid | (493) | (312) | (786) |
Cash generated from operating activities | 4,058 | 1,635 | 4,130 |
|
|
|
|
Cash flows from investing activities |
|
|
|
Capital expenditure on fixed assets | (109) | (226) | (506) |
Sale of property plant and equipment | - | 3 | - |
Expenditure on development and other intangibles | (116) | (257) | (582) |
Acquisition of subsidiaries, net of cash | - | - | (5,182) |
Net cash used in investing activities | (225) | (480) | (6,270) |
|
|
|
|
Cash flows from financing activities |
|
|
|
Payments of lease liabilities | (224) | (225) | (511) |
Foreign exchange movements | 107 | - | - |
Proceeds from bank borrowings | - | - | 6,496 |
Repayment of borrowings | (5,562) | (700) | (1,143) |
Issues of shares | - | - | 80 |
Net cash (used in)/from financing activities | (5,679) | (925) | 4,922 |
|
|
|
|
Net (decrease)/increase in cash and cash equivalents |
(1,846) |
230 | 2,782 |
|
|
|
|
Cash and cash equivalents, beginning of period | 5,290 | 2,494 | 2,494 |
Foreign currency movements on cash balances | (8) | 3 | 14 |
Cash and cash equivalents, end of period | 3,436 | 2,727 | 5,290 |
Consolidated statement of changes in equity
Unaudited for the six months ended 31 October 2020
6 months to 31 October 2020 - unaudited |
Share capital £'000 |
Merger reserve £'000 |
Foreign exchange £'000 |
Share premium £'000 |
Own shares held by EBT £'000 |
Share-based payment reserve £'000 |
Retained earnings £'000 |
Total £'000 |
Balance at 1 May 2020 |
975 |
3,030 |
181 |
8,746 |
- |
467 |
6,665 |
20,064 |
Shares issued |
3 |
- |
- |
59 |
- |
- |
- |
62 |
Share based payments |
- |
- |
- |
- |
- |
152 |
- |
152 |
Transactions with owners |
3 |
- |
- |
59 |
- |
152 |
- |
214 |
Profit for the period |
- |
- |
- |
- |
- |
- |
1,978 |
1,978 |
Foreign exchange on consolidation of subsidiaries |
- |
- |
48 |
- |
- |
- |
- |
48 |
Total comprehensive income for the period |
- |
- |
48 |
- |
- |
- |
1,978 |
2,026 |
Balance at 31 October 2020 |
978 |
3,030 |
229 |
8,805 |
- |
619 |
8,643 |
22,304 |
6 months to 31 October 2019 - unaudited |
Share capital £'000 |
Merger reserve £'000 |
Foreign exchange £'000 |
Share premium £'000 |
Own shares held by EBT £'000 |
Share-based payment reserve £'000 |
Retained earnings £'000 |
Total £'000 |
Balance at 1 May 2019 |
972 |
3,030 |
140 |
8,696 |
(17) |
284 |
3,981 |
17,086 |
Share based payments |
- |
- |
- |
- |
- |
140 |
- |
140 |
Release of shares on option exercise |
- |
- |
- |
- |
17 |
- |
- |
17 |
Transactions with owners |
- |
- |
- |
- |
17 |
140 |
- |
157 |
Profit for the period |
- |
- |
- |
- |
- |
- |
1,328 |
1,328 |
Foreign exchange on consolidation of subsidiaries |
- |
- |
26 |
- |
- |
- |
- |
26 |
Total comprehensive income for the period |
- |
- |
26 |
- |
- |
- |
1,328 |
1,354 |
Balance at 31 October 2019 |
972 |
3,030 |
166 |
8,696 |
- |
424 |
5,309 |
18,597 |
12 months to 30 April 2020 - audited |
Share capital £'000 |
Merger reserve £'000 |
Foreign exchange £'000 |
Share premium £'000 |
Own shares held by EBT £'000 |
Share-based payment reserve £'000 |
Retained earnings £'000 |
Total £'000 |
Balance at 30 April 2019 |
972 |
3,030 |
140 |
8,696 |
(17) |
284 |
3,981 |
17,086 |
Restatement for IFRS16 ("Leases") |
- |
- |
- |
- |
- |
- |
- |
- |
Adjusted balances at 30 April 2019 |
972 |
3,030 |
140 |
8,696 |
(17) |
284 |
3,981 |
17,086 |
Shares issued |
3 |
- |
- |
50 |
17 |
- |
- |
70 |
Share-based payments transfer |
- |
- |
- |
- |
- |
(93) |
93 |
- |
Share based payments |
- |
- |
- |
- |
- |
276 |
- |
276 |
Transactions with owners |
3 |
- |
- |
50 |
17 |
183 |
93 |
346 |
Profit for the year |
- |
- |
- |
- |
- |
- |
2,591 |
2,591 |
Foreign exchange on consolidation of subsidiaries |
- |
- |
41 |
- |
- |
- |
- |
41 |
Total comprehensive income |
- |
- |
41 |
- |
- |
- |
2,591 |
2,632 |
Balance at 30 April 2020 |
975 |
3,030 |
181 |
8,746 |
- |
467 |
6,665 |
20,064 |
Notes to the interim financial statements
1. General information and basis of preparation
SDI Group plc (formerly known as Scientific Digital Imaging plc (the "Company")), a public limited company, is the Group's ultimate parent. It is registered in England and Wales. The consolidated interim financial statements of the Company for the period ended 31 October 2020 comprise the Company and its subsidiaries (together referred to as the "Group").
The unaudited consolidated interim financial statements are for the six months ended 31 October 2020. These interim financial statements have been prepared using the recognition and measurement principles of International Accounting Standards, International Financial Reporting Standards and Interpretations adopted for use in the European Union (collectively EU IFRS). The consolidated interim financial information has been prepared under the historical cost convention, as modified by the recognition of certain financial instruments at fair value. The consolidated interim financial statements are presented in British pounds (£), which is also the functional currency of the ultimate parent company.
The consolidated interim financial information was approved by the Board of Directors on 8 December 2020
The financial information set out in this interim report does not constitute statutory accounts as defined in section 435 of the Companies Act 2006. The figures for the year ended 30 April 2020 have been extracted from the statutory financial statements of SDI Group plc which have been filed with the Registrar of Companies. The auditor's report on those financial statements was unqualified and did not contain a statement under section 498(2) or 498(3) of the Companies Act 2006. The financial information for the six months ended 31 October 2020 and for the six months ended 31 October 2019 has not been audited.
2. Principal accounting policies
The principal accounting policies adopted in the preparation of the condensed consolidated interim information are consistent with those followed in the preparation of the Group's financial statements for the year ended 30 April 2020.
The accounting policies have been applied consistently throughout the Group for the purposes of preparation of these interim financial statements.
3. Alternative Performance Measures
The Group uses Adjusted Operating Profit, Adjusted Profit Before Tax, Adjusted EPS and Net Operating Assets as supplemental measures of the Group's profitability and investment in business-related assets, in addition to measures defined under IFRS. The Group considers these useful due to the exclusion of specific items that are considered to hinder comparison of underlying profitability and investments of the Group's segments and businesses, and is aware that shareholders use these measures to evaluate performance over time. The adjusting items for the alternative measures of profit are either recurring but non-cash charges (share-based payments and amortisation of acquired intangible assets) or exceptional items (reorganisation costs and acquisition and fundraising costs).
The following table is included to define the term Adjusted Operating Profit:
| 6 months to 31 October 2020 Unaudited £'000 | 6 months to 31 October 2019 Unaudited £'000 | 12 months to 30 April 2020 Audited £'000 |
|
|
|
|
Operating Profit (as reported) | 2,535 | 1,621 | 3,511 |
|
|
|
|
Adjusting items (all costs): |
|
|
|
Non-underlying items |
|
|
|
Share based payments | 152 | 140 | 276 |
Amortisation of acquired intangible assets | 379 | 282 | 647 |
Exceptional items |
|
|
|
Reorganisation costs | 129 | 59 | 110 |
Acquisition and fundraising costs | - | - | 58 |
Total adjusting items within Operating Profit | 660 | 481 | 1,091 |
|
|
|
|
Adjusted Operating Profit | 3,195 | 2,102 | 4,602 |
Adjusted Profit Before Tax is defined as follows:
| 6 months to 31 October 2020 Unaudited £'000 | 6 months to 31 October 2019 Unaudited £'000 | 12 months to 30 April 2020 Audited £'000 |
|
|
|
|
Profit before tax (as reported) | 2,371 | 1,517 | 3,257 |
|
|
|
|
Adjusting items (as above) | 660 | 481 | 1,091 |
|
|
|
|
Adjusted Profit Before Tax | 3,031 | 1,998 | 4,348 |
3. Alternative Performance Measures (continued)
Adjusted EPS is defined as follows:
| 6 months to 31 October 2020 Unaudited £'000 | 6 months to 31 October 2019 Unaudited £'000 | 12 months to 30 April 2020 Audited £'000 |
|
|
|
|
Profit for the period (as reported) | 1,978 | 1,328 | 2,591 |
|
|
|
|
Adjusting items (as above) | 660 | 481 | 1,091 |
Less: taxation on adjusting items calculated at the UK statutory rate |
(125) |
(91) |
(207) |
Adjusted net profit | 2,513 | 1,718 | 3,475 |
|
|
|
|
Divided by diluted weighted average number of shares in issue (Note 5) | 101,611,426 | 100,846,707 | 101,206,148 |
|
|
|
|
|
|
|
|
Adjusted diluted EPS | 2.47p | 1.70p | 3.43p |
Net Operating Assets is defined as follows:
| 31 October 2020 Unaudited £'000 | 31 October 2019 Unaudited £'000 | 30 April 2020 Audited £'000 |
|
|
|
|
Net assets | 22,304 | 18,597 | 20,064 |
|
|
|
|
Deferred tax asset | 219 | 182 | 246 |
Corporation tax asset | 79 | - | 52 |
Cash and cash equivalents | 3,436 | 2,727 | 5,290 |
Borrowings (current and non-current) | (6,544) | (5,807) | (12,286) |
Deferred tax liability | (2,037) | (1,356) | (2,134) |
Current tax payable | (510) | (597) | (513) |
Total adjusting items within Net assets | (5,357) | (4,851) | (9,345) |
|
|
|
|
Net Operating Assets | 27,661 | 23,448 | 29,409 |
4. Segmental analysis
| 6 months to 31 October 2020 Unaudited
£'000 | 6 months to 31 October 2019 Unaudited £'000 | 12 months to 30 April 2020 Audited
£'000 |
Revenues |
|
|
|
Digital Imaging | 6,940 | 5,639 | 11,050 |
Sensors & Control | 7,186 | 5,806 | 13,448 |
Other | - | - | - |
Group | 14,126 | 11,445 | 24,498 |
|
|
|
|
Adjusted Operating Profit |
|
|
|
Digital Imaging | 2,075 | 1,210 | 2,382 |
Sensors & Control | 1,569 | 1,361 | 3,028 |
Other | (449) | (469) | (808) |
Group | 3,195 | 2,102 | 4,602 |
|
|
|
|
Amortisation of acquired intangible assets |
|
|
|
Digital Imaging | (92) | (90) | (182) |
Sensors & Control | (291) | (192) | (465) |
Other | - | - | - |
Group | (383) | (282) | (647) |
A reconciliation of Adjusted Operating Profit to Operating Profit for the Group is provided in Note 3.
Analysis of amortisation of acquired intangible assets has been included separately as the Group considers it to be an important component of profit which is directly attributable to the reported segments.
The Other category includes costs which cannot be allocated to the other segments, and consists principally of Group HQ costs.
4. Segmental analysis (continued)
| 31 October 2020 Unaudited
£'000 | 31 October 2019 Unaudited
£'000 | 30 April 2020 Audited
£'000 |
Operating assets excluding acquired intangible assets |
|
|
|
Digital Imaging | 6,942 | 6,508 | 6,281 |
Sensors & Control | 5,825 | 4,110 | 5,993 |
Other | 331 | 53 | 120 |
Group | 13,098 | 10,671 | 12,394 |
|
|
|
|
Acquired intangible assets |
|
|
|
Digital Imaging | 5,282 | 5,461 | 5,370 |
Sensors & Control | 14,777 | 10,260 | 15,068 |
Other | - | - | - |
Group | 20,059 | 15,721 | 20,438 |
|
|
|
|
Liabilities |
|
|
|
Digital Imaging | (3,051) | (1,185) | (1,190) |
Sensors & Control | (2,200) | (1,514) | (2,087) |
Other | (245) | (245) | (158) |
Group | (5,496) | (2,944) | (3,435) |
|
|
|
|
Net Operating Assets |
|
|
|
Digital Imaging | 9,173 | 10,784 | 10,550 |
Sensors & Control | 18,402 | 12,856 | 19,042 |
Other | 86 | (192) | (183) |
Group | 27,661 | 23,448 | 29,409 |
A reconciliation of Net Operating Assets to net assets for the Group is provided in Note 3.
5. Earnings per share
The calculation of the basic earnings per share is based on the profits attributable to the shareholders of SDI Group plc divided by the weighted average number of shares in issue during the period. All profit per share calculations relate to continuing operations of the Group.
| Profit attributable to shareholders £'000 | Weighted average number of shares | Earnings per share amount in pence |
Basic earnings per share: |
|
|
|
Period ended 31 October 2020 | 1,978 | 97,582,755 | 2.03 |
Period ended 31 October 2019 | 1,328 | 97,203,951 | 1.37 |
Year ended 30 April 2020 | 2,591 | 97,277,721 | 2.66 |
|
|
|
|
Dilutive effect of share options: |
|
|
|
Period ended 31 October 2020 |
| 4,028,671 |
|
Period ended 31 October 2019 |
| 3,642,756 |
|
Year ended 30 April 2020 |
| 3,928,426 |
|
|
|
|
|
Diluted earnings per share: |
|
|
|
Period ended 31 October 2020 | 1,978 | 101,611,426 | 1.95 |
Period ended 31 October 2019 | 1,328 | 100,846,707 | 1.32 |
Year ended 30 April 2020 | 2,591 | 101,206,147 | 2.56 |
6. Borrowings
| 31 October 2020 £'000 | 31 October 2019 £'000 | 30 April 2020 £'000 |
Within one year: |
|
|
|
Bank finance | 1,371 | - | 1,371 |
Lease liabilities | 562 | 449 | 539 |
| 1,933 | 449 | 1,910 |
After one year and within five years: |
|
|
|
Bank finance | 2,400 | 3,300 | 7,962 |
Lease liabilities | 1,297 | 1,103 | 2,414 |
| 3,697 | 4,403 | 10,376 |
After more than five years: |
|
|
|
Lease liabilities | 914 | 955 | - |
|
|
|
|
Total borrowings | 6,544 | 5,807 | 12,286 |
Bank finance relates to amounts drawn down under the Group's bank facility with HSBC Bank plc, which is secured against all assets of the Group. The facility consists of a revolving facility of £5m and an amortising facility which reduces in quarterly instalments from £4.8m when it was taken out in November 2019 to zero by April 2023, when the current agreement expires. The facility has covenants relating to leverage (net debt to EBITDA), interest coverage, and cashflow to debt service.
7. Post Balance Sheet Event
On 2 December 2020 the Group completed the acquisition of Monmouth Scientific Limited ("Monmouth Scientific") for an initial consideration of £2.66m in cash and shares in SDI Group plc plus further payments up to a maximum total consideration of £6.94 million depending on net assets delivered at completion and on profits made by Monmouth Scientific in the 12 months to 31 March 2021. Monmouth Scientific specialises in providing controlled clean air environments for scientific, medical and other technical applications. For the year ended 31 March 2020, Monmouth Scientific achieved revenue of £6.2m and profit before tax of £0.28m. The acquisition is expected to be immediately earnings enhancing.
SDl Group plc
Beacon House
Nuffield Road
Cambridge
CB4 1TF
UK
Telephone: +44 (0)1223 727144
Fax: +44 (0)1223 727101
Email: info@thesdigroup.net